Mar 24, 2019
Graham Kelly, CEO, Noxopharm discusses the company's lead clinical asset, Veyonda, a first-in-class chemotherapy and radiation enhancer that has immuno-oncology properties. Veyonda has potential utility across solid tumors and boosts the effect of radiation therapy 2-3x in cancer cells. It has already shown positive results in patients with metastatic castrate-resistant prostate cancer.
#oncology #prostatecancer #radiation #chemotherapy